|
|
 | | | |
- close
- close
- close
- close
Merrimack Pharmaceuticals (MACK) |
Benzinga
May 6
Comment
Merrimack Pharmaceuticals (NASDAQ: MACK) shares touched a new 52-week low of $4.145. Merrimack' trailing-twelve-month profit margin is -186.58%.
Ecopetrol SA (NYSE: EC) shares reached a new 52-week low of $45.30 on Q1 results.
Coca-Cola...
StreetInsider.com
Apr 15
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Merrimack+Pharmaceuticals+%28MACK%29+Completes+Enrollment+in+Phase+2+Study+of+MM-121+in+HER2-Negative+Breast+Cancer/8251886.html for the full story.
StreetInsider.com
Mar 14
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Merrimack+Pharm+%28MACK%29+Posts+Wider+than+Expected+Q4+Loss/8184380.html for the full story.
StreetInsider.com
Feb 1
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/Merrimack+Pharma+%28MACK%29+Files+%24200M+Mixed+Shelf/8051184.html for the full story.
StreetInsider.com
Jan 23
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Merrimack+Pharma+%28MACK%29+Will+Present+Preclinical+Data+for+MM-111/8025027.html for the full story.
Wall Street Journal
Dec 26
Comment
The business of investing in portfolios of distressed single-family homes has come to the point in its current cycle that investors who got into the game early are beginning to cash out.
StreetInsider.com
Nov 14
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Merrimack+Pharm+%28MACK%29+Reports+Q3+Loss+of+%241.81/7874851.html for the full story.
Benzinga
Oct 3
Comment
Here is a quick look at three top-performing biotech stocks, each with a consensus recommendation (among analysts) of Strong Buy. They are Ariad Pharmaceuticals (NASDAQ: ARIA), Merrimack Pharmaceuticals (NASDAQ: MACK) and Synageva BioPharma...
Benzinga
Sep 25
Comment
Odyssey Marine Exploration (NASDAQ: OMEX) fell 30.62% to $2.56 at 9:55 am. Odyssey Marine Exploration provided an operations update on several projects.
Gevo (NASDAQ: GEVO) shares dipped 29% to $2.35. Analysts at Cowen downgraded Gevo from...
Benzinga
Aug 31
Comment
Bank of America initiated its coverage on Merrimack Pharmaceuticals (NASDAQ: MACK) with a Buy rating and a price objective of $13 a share on the company's novel drug platform.
Bank of America noted, "Merrimack is a currently loss-making...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS|
Error creating thumbnail: convert: unable to open image `/home/wikinvest/src_live_1/mediawiki/images/c/ce/IPO.jpg': No such file or directory @ blob.c/OpenBlob/2480. convert: missing an image filename `/home/wikinvest/src_live_1/mediawiki/images/thumb/c/ce/IPO.jpg/40px-IPO.jpg' @ convert.c/ConvertImageCommand/2800. |
This company completed an initial public offering (IPO) of its stock in 2010. View articles that reference this company. Recent IPOs: Globe Specialty Metals • LogMeIn • Invesco Mortgage Capital • Medidata • Chemspec |
Merrimack Pharmaceuticals (NASDAQ:MACK)
Business Overview
New Updates
The company's initial public offering of stock on the NASDAQ occurred on March 28, 2012. The company offered 14.3M shares each for $7. This was at the low end of the initial price range of $8-$10. The company had originally announced that they would offer 16.67M shares. The deal raised a total of approximately $100M. The lead manger of the deal was JP Morgan.[1]
Trends & Forces
| |||||||
